Metronidazolo Kabi

Metronidazole, the active ingredient in Metronidazolo Kabi, is a nitroimidazole presented as an intravenous solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in hospitalized patients.

GNH USA supplies Metronidazolo Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is employed to manage infections caused by anaerobic bacteria and susceptible protozoa. It is indicated for several clinical conditions: - Anaerobic bacterial infections: eradicates susceptible anaerobes, reducing infection severity. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms. - Amoebic dysentery: kills Entamoeba histolytica trophozoites, controlling intestinal disease. - Clostridioides difficile infection (adjunct): reduces toxin‑producing bacterial load when used with standard therapy.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Metallic taste: transient alteration of taste perception. - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Seizures: rare neurologic events. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome: severe skin detachment. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Neutropenia: marked reduction in white blood cells.

Metronidazole requires careful use in specific patient populations and clinical situations. - Renal impairment: assess renal function and adjust therapy as needed. - Hepatic dysfunction: monitor liver enzymes during treatment. - Pregnancy Category B: use only when clearly indicated. - Alcohol consumption: avoid to prevent disulfiram‑like reactions. - Concurrent antibiotics: evaluate for additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metronidazole interacts with several medicines; some combinations should be avoided while others need monitoring.

Major Interactions (Avoid): - Alcohol: may cause severe flushing and nausea. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce efficacy, consider backup method. - Cimetidine: can increase metronidazole plasma concentrations. - Rifampin: may lower metronidazole levels, reducing effectiveness.